rapidli
expand
literatur
vitro
antivir
activ
drug
may
repurpos
therapi
chemoprophylaxi
howev
accompani
comprehens
evalu
abil
drug
achiev
target
plasma
lung
concentr
follow
approv
dose
human
moreov
public
focuss
maximum
effect
concentr
may
insuffici
robust
indic
antivir
activ
mark
differ
slope
concentrationrespons
curv
drug
accordingli
vitro
activ
data
digitis
avail
public
th
april
use
recalcul
valu
drug
valu
express
ratio
achiev
maximum
plasma
concentr
cmax
report
drug
administr
approv
dose
human
ratio
analys
drug
achiev
ratio
mean
plasma
cmax
concentr
exceed
necessari
inhibit
replic
indepth
assess
put
agent
test
demonstr
nitazoxanid
nelfinavir
tipranavir
boost
ritonavir
sulfadoxin
achiev
plasma
concentr
report
activ
across
entir
approv
dose
interv
approv
human
dose
drug
report
unbound
lung
plasma
tissu
partit
coeffici
kpulung
also
simul
use
along
report
cmax
fraction
unbound
plasma
deriv
lung
better
indic
potenti
human
efficaci
lung
ratio
also
calcul
limit
number
drug
use
paramet
hydroxychloroquin
chloroquin
mefloquin
atazanavir
boost
ritonavir
tipranavir
boost
ritonavir
ivermectin
azithromycin
lopinavir
boost
ritonavir
predict
achiev
lung
concentr
higher
report
analysi
possibl
nelfinavir
insuffici
data
avail
calcul
kpulung
nitozoxanid
sulfadoxin
also
predict
exceed
report
lung
respect
antivir
activ
data
report
date
acquir
differ
laboratori
condit
across
multipl
group
appli
variabl
level
stringenc
howev
analysi
may
use
select
potenti
candid
clinic
test
deprioritis
compound
unlik
attain
target
concentr
antivir
activ
futur
studi
focu
valu
discuss
find
context
achiev
exposur
human
especi
within
target
compart
lung
order
maximis
potenti
success
propos
human
clinic
trial
coronaviru
respiratori
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
infect
fever
persist
cough
respiratori
symptom
common
patient
report
vomit
nausea
abdomin
pain
diarrhoea
date
specif
treatment
avail
result
signific
morbid
mortal
global
accord
intern
clinic
trial
registri
platform
search
portal
clinic
trial
regist
rapidli
expand
pandem
warrant
urgent
develop
strategi
particularli
protect
peopl
high
risk
infect
repurpos
current
avail
drug
utilis
clinic
known
safeti
profil
quickest
way
address
seriou
unmet
clinic
need
antivir
drug
urgent
requir
treatment
patient
mildmoder
diseas
prevent
worsen
symptom
reduc
burden
upon
healthcar
system
howev
differ
approach
like
need
patient
alreadi
critic
state
due
immun
dysregul
appar
sever
case
previou
investig
shown
entri
sarscov
occur
via
angiotensin
convert
enzym
receptor
studi
normal
lung
tissu
show
cell
alveolar
epitheli
type
ii
cell
highlight
lung
primari
target
organ
facilit
viral
invas
replic
furthermor
receptor
also
highli
express
gastrointestin
epitheli
cell
rna
observ
present
stool
specimen
patient
infect
recent
retrospect
analysi
patient
laboratori
confirm
also
indic
infect
human
kidney
tubul
induc
acut
tubular
damag
patient
furthermor
patient
exhibit
liver
comorbid
note
observ
sar
middl
east
respiratori
syndrom
mer
tropism
gastrointestin
tract
caus
liver
impair
addit
respiratori
diseas
genom
similar
sarscov
sequenc
ident
would
impli
current
viru
would
act
similar
manner
present
within
bodi
system
therefor
treatment
option
provid
therapeut
concentr
drug
within
system
circul
affect
organ
like
requir
absenc
vaccin
antivir
drug
could
also
deploy
chemoprophylaxi
protect
infect
would
present
essenti
tool
protect
healthcar
staff
key
worker
well
household
contact
alreadi
infect
chemoprevent
drug
need
penetr
multipl
site
infect
occur
suffici
concentr
inhibit
viral
replic
may
includ
mucou
membran
present
nasal
caviti
throat
ocular
surfac
tear
upper
respiratori
tractlung
howev
therapeut
concentr
may
need
system
circul
chemoprophylaxi
yet
determin
although
difficult
scarc
studi
work
anim
shown
size
inoculum
respiratori
virus
influenza
associ
sever
result
diseas
report
indic
higher
viral
load
indic
poorer
prognosi
correl
sever
symptom
viral
load
sever
case
report
time
higher
mild
case
light
even
chemoprophylact
drug
reduc
inoculum
size
without
complet
block
transmiss
major
benefit
morbid
mortal
may
still
achiev
mani
ongo
global
research
effort
focus
screen
activ
exist
compound
vitro
order
identifi
candid
repurpos
howev
current
data
yet
systemat
analys
context
plasma
target
site
exposur
achiev
administr
approv
dose
human
purpos
work
evalu
exist
vitro
data
determin
prioritis
drug
capabl
reach
antivir
concentr
within
blood
plasma
accept
physiologicallybas
pharmacokinet
pbpk
equat
also
use
predict
expect
concentr
lung
order
assess
potenti
drug
therapi
key
diseas
site
potenti
chemoprevent
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
identifi
compound
relev
potenc
pharmacokinet
data
perform
literatur
search
pubm
googl
scholar
biorxiv
medrxiv
chemrxiv
follow
search
term
use
vitro
activ
data
antivir
pharmacokinet
data
cmax
pharmacokinet
use
along
drug
name
drug
report
activ
april
th
clinic
pharmacokinet
data
obtain
food
drug
administr
fda
european
medicin
agenc
ema
public
avail
onlin
indic
degre
candid
drug
expect
accumul
lung
presum
site
primari
efficaci
prevent
infect
provid
calcul
unbound
lung
plasma
tissu
partit
coeffici
kpulung
accord
methodolog
rodger
rowland
formula
provid
method
use
physicochem
properti
drug
pka
log
p
classif
acidbaseneutr
vitro
drug
bind
inform
fraction
unbound
plasma
blood
plasma
ratio
combin
tissu
specif
data
lipid
content
volum
intraextracellular
water
etc
predict
tissu
kpu
valu
predict
kpulung
convert
kplung
multipli
fraction
unbound
plasma
allow
estim
lung
exposur
vivo
measur
plasma
concentr
absenc
observ
tissu
distribut
data
rodger
rowland
method
accept
mean
provid
initi
estim
tissu
partit
pbpk
model
known
limit
potenti
accuraci
gener
predict
kpu
within
fold
observ
tissu
kpu
valu
sinc
major
paper
valu
avail
concentrationrespons
data
digit
use
web
plot
softwar
graph
replot
sigmaplot
systat
softwar
inc
curv
fit
confirm
valu
determin
valu
ratio
calcul
drug
previou
evid
clinic
use
human
avail
human
pharmacokinet
data
avail
lung
kpu
valu
also
use
combin
report
cmax
valu
deriv
estim
lung
exposur
cmax
identifi
key
studi
detail
antivir
activ
compound
tabl
seventeen
molecul
report
cmax
valu
greater
least
one
report
valu
includ
nelfinavir
chloroquin
remdesivir
lopinavir
boost
ritonavir
eltrombopag
hydroxychloroquin
atazanavir
boost
ritonavir
indomethacin
favipiravir
sulfadoxin
nicolsamid
mefloquin
tipranavir
boost
ritonavir
ritonavir
merimepodib
anidulafungin
nitazoxanid
howev
note
amodiaquin
atazanavir
chloroquin
hydroxychloroquin
lopinavir
mefloquin
nelfinavir
remdesevir
toremefin
one
valu
report
across
avail
literatur
alway
agreement
figur
moreov
variabl
report
valu
sometim
result
cmax
ratio
give
differ
estim
like
valu
molecul
mean
drug
cmax
ratio
could
figur
amodiaquin
toremifen
report
valu
report
cmax
nelfinavir
report
cmax
expect
exceed
report
valu
atazanavir
chloroquin
hydroxychloroquin
lopinavir
mefloquin
remdesivir
valu
cmax
wherea
observ
dramat
highlight
sensit
current
analysi
report
antivir
activ
data
taken
account
interpret
data
present
hereaft
report
antivir
activ
data
cover
suffici
concentr
rang
avail
digitis
subsequ
calcul
valu
remaind
possibl
calcul
drug
avail
rank
accord
ratio
figur
drug
valu
achiev
plasma
concentr
concentr
report
inhibit
replic
eltrombopag
favipiravir
remdesevir
nelfinavir
niclosamid
nitazoxanid
tipranavir
estim
exceed
least
one
report
cmax
concentr
anidulafungin
lopinavir
chloroquin
ritonavir
also
report
exceed
least
one
report
valu
cmax
less
lung
kpu
simul
molecul
necessari
physicochem
properti
vitro
drug
bind
inform
avail
kpulung
use
along
fraction
unbound
plasma
fu
plasma
cmax
valu
calcul
predict
figur
lung
data
shown
drug
ebselen
merimepodib
niclosamid
remdesivir
fraction
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
unbound
data
unavail
drug
benztropin
indinavir
loperamid
nelfinavir
saquinavir
toremifen
blood
plasma
ratio
unavail
drug
camostat
emetin
fluspirilen
umifenovir
fraction
unbound
blood
plasma
ratio
unavail
therefor
drug
exclud
analysi
total
drug
avail
data
predict
give
concentr
lung
least
one
report
figur
predict
exceed
rank
order
lung
ratio
chloroquin
atazanavir
boost
ritonavir
tipranavir
boost
ritonavir
hydroxychloroquin
mefloquin
ivermectin
lopinavir
boost
ritonavir
azithromycin
ritonavir
gilteritinib
nitazoxanid
imantinib
oxprenolol
data
exclud
due
analysi
possibl
drug
systemat
develop
mechanismbas
inhibitor
key
target
involv
viral
replic
pathogenesi
like
result
highli
effect
safe
medicin
come
year
howev
repurpos
alreadi
approv
medicin
antivir
treatment
chemoprevent
strategi
undoubtedli
fastest
way
bring
forward
therapeut
option
urgent
unmet
need
pose
rang
differ
drug
drug
class
demonstr
display
vari
degre
antivir
activ
vitro
mani
drug
alreadi
licenc
use
human
rang
indic
howev
current
data
emerg
global
screen
effort
routin
benchmark
prioritis
achiev
concentr
administr
dose
proven
accept
safeti
profil
human
current
analysi
indic
drug
report
antivir
activ
like
achiev
plasma
exposur
requir
antivir
activ
least
dose
interv
notabl
neither
chloroquin
hydroxychloroquin
lopinavirritonavir
exhibit
sustain
plasma
concentr
report
across
report
dose
interv
ultim
implic
therapi
depend
upon
whether
system
suppress
prerequisit
reduct
morbid
mortal
rais
concern
ongo
trial
drug
chloroquin
hydroxychloroquin
lopinavirritonavir
howev
predict
lung
accumul
rather
plasma
exposur
may
provid
therapi
advantag
andor
give
reassur
ongo
chemoprevent
trial
least
candid
achiev
cmax
one
report
deriv
alreadi
clinic
evalu
treatment
includ
remdesivir
favipiravir
lopinavirritonavir
chloroquin
robust
antivir
activ
data
found
galidesrivir
conduct
analysi
also
clinic
investig
recent
trial
favipirivir
demonstr
success
improv
arbidol
p
patient
without
risk
factor
critic
case
patient
hypertens
andor
diabet
result
compassion
use
remdesivir
sever
ill
patient
also
recent
report
confirm
ongo
random
placebocontrol
trial
serv
valid
candid
present
author
unawar
ongo
trial
candid
molecul
cmax
report
none
report
wwwclinicaltrialsgov
time
manuscript
submiss
th
april
particular
interest
nitazoxanid
tipranavir
sulfadoxin
nelfinavir
may
expect
sustain
plasma
pharmacokinet
exposur
lowest
report
deriv
avail
durat
approv
dose
dose
interv
nitazoxanid
antiprotozo
drug
previous
demonstr
display
broad
antivir
activ
human
anim
coronavirus
well
variou
strain
influenza
importantli
nitazoxanid
rapidli
metabolis
tizoxanid
human
activ
metabolit
investig
tizoxanid
report
exhibit
similar
activ
nitazoxanid
virus
well
pathogen
mechan
antivir
action
fulli
understood
nitazoxanid
report
affect
viral
genom
synthesi
prevent
viral
entri
interfer
nglycosyl
matur
influenza
hemagglutinin
notabl
spike
protein
also
highli
nglycosyl
drug
also
shown
elicit
innat
immun
respons
potenti
product
type
interferon
phase
clinic
trial
demonstr
reduct
symptom
viral
shed
patient
uncompl
influenza
safeti
nitazoxanid
well
understood
fulli
investig
renal
hepat
impair
antivir
activ
nitazoxanid
requir
studi
exist
data
drug
encourag
niclosamid
anoth
antiprotozo
drug
exhibit
broad
antivir
activ
due
abil
perturb
phdepend
membran
fusion
requir
viru
entri
report
impact
upon
attach
entri
merscov
niclosamid
observ
inhibit
activ
impair
viral
replic
niclosamid
report
well
toler
influenc
vital
organ
function
howev
low
aqueou
solubl
poor
oral
bioavail
despit
higher
report
potenc
nitazoxanid
ratio
slightli
lower
pauciti
publish
pharmacokinet
data
niclosamid
prohibit
thorough
investig
exposur
relat
activ
entir
dose
interv
nitazoxanid
niclosamid
also
report
potent
antagonist
calcium
activ
chlorid
channel
modul
bronchodil
tipranavir
nelfinavir
hiv
proteas
inhibitor
drug
rank
highli
term
cmax
ratio
moreov
indepth
analysi
demonstr
concentr
across
dose
interv
drug
remain
calcul
valu
approv
dose
schedul
unlik
nelfinavir
tipranavir
coadminist
low
dose
ritonavir
boost
pharmacokinet
via
inhibit
sinc
ritonavir
report
exert
activ
could
advantag
would
need
balanc
much
higher
risk
drugdrug
interact
could
neg
impact
patient
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
longterm
toxic
may
less
concern
shorter
term
exposur
prove
success
sulfadoxin
anoth
antimalari
drug
usual
administ
combin
pyrimethamin
folic
acid
antagonist
combin
sulfadoxin
inhibit
activ
dihydroptero
synthas
within
malaria
parasit
mechan
action
unclear
also
note
author
find
data
describ
antivir
activ
drug
virus
also
concentr
use
vitro
activ
use
analysi
high
enough
reach
calcul
valu
therefor
like
molecul
describ
manuscript
vitro
activ
repeat
notwithstand
sulfadoxin
plasma
concentr
far
report
maintain
patient
receiv
singl
mg
dose
mg
pyrimethamin
day
compar
report
molecul
sulfadoxin
expect
high
accumul
lung
concentr
higher
estim
analysi
lung
kpu
therefor
report
antivir
activ
confirm
drug
may
offer
opportun
therapi
andor
chemoprophylaxi
consid
impact
sever
diseas
occur
lung
tissu
may
key
site
transmiss
potenti
candid
drug
accumul
lung
tissu
consid
analysi
predict
lung
cmax
ratio
reveal
candid
expect
exceed
concentr
need
antivir
activ
tissu
hydroxychloroquin
chloroquin
mefloquin
atazanavir
boost
ritonavir
tipranavir
boost
ritonavir
ivermectin
lopinavir
predict
achiev
lung
concentr
higher
report
drug
also
predict
exceed
lung
least
data
shown
lung
predict
possibl
nelfinavir
insuffici
data
avail
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
calcul
kpulung
nitozoxanid
sulfadoxin
also
predict
exceed
report
lung
respect
nitazoxanid
predict
exceed
lung
calcul
avail
data
sulfadoxin
inflamm
injuri
chang
vascular
microenviron
could
profound
effect
abil
drug
accumul
lung
cell
due
recruit
neutrophil
leaki
endotheli
cell
lung
inflammatori
microenviron
character
increas
bodi
temperatur
excess
enzym
activ
importantli
low
interstiti
ph
case
chloroquin
hydroxychloroquin
diprot
weak
base
exquisit
depend
ph
gradient
drive
lysosom
uptak
mechan
lung
accumul
demonstr
cellular
chloroquin
uptak
diminish
one
hundredfold
everi
ph
unit
extern
acidif
situat
like
deterior
mechan
ventil
also
induc
acidif
lung
tissu
independ
inflamm
therefor
benefit
lung
accumul
mani
drug
may
lost
treatment
sever
infect
convers
mefloquin
monoprot
lipophil
chloroquin
may
make
much
less
reliant
ph
gradient
drive
cellular
accumul
lung
like
charg
form
drug
suffici
lipophil
allow
movement
across
biolog
membran
along
concentr
gradient
two
studi
describ
mefloquin
uptak
cell
one
studi
suggest
mefloquin
uptak
energydepend
suggest
mefloquin
uptak
mediat
secondari
activ
transport
rather
passiv
proton
trap
mefloquin
known
caus
sever
psychiatr
side
effect
patient
use
drug
manag
care
therefor
mefloquin
may
offer
opportun
treatment
sever
diseas
avail
drug
current
test
therapi
high
lung
exposur
proven
empir
drug
list
may
also
prove
valuabl
chemoprevent
strategi
studi
repres
first
holist
view
drug
report
activ
context
achiev
pharmacokinet
exposur
human
analysi
provid
basi
ration
select
candid
analysi
import
limit
firstli
cmax
pharmacokinet
paramet
univers
avail
candid
drug
cmin
valu
gener
accept
better
marker
efficaci
sinc
repres
lowest
plasma
concentr
dose
interv
howev
cmax
use
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
assess
whether
plasma
concentr
would
exceed
requir
point
dose
interv
follow
indepth
analysi
promis
candid
secondli
valu
equat
concentr
requir
suppress
viru
data
unavail
calcul
valu
drug
valu
prefer
marker
activ
slope
concentrationrespons
curv
vari
substanti
differ
molecul
differ
mechan
action
although
calcul
drug
author
deem
appropri
deprioritis
molecul
achiev
cmax
analysi
thirdli
report
antivir
activ
conduct
differ
condit
tabl
sever
case
vari
molecul
assess
differ
studi
figur
mitig
strategi
possibl
limit
data
interpret
context
qualiti
avail
data
may
profoundli
impact
conclus
furthermor
vitro
activ
confirm
promis
candid
fourthli
plasma
protein
bind
import
factor
determin
whether
suffici
free
drug
concentr
avail
exert
antivir
activ
insuffici
data
avail
across
dataset
determin
protein
bindingadjust
valu
import
highli
protein
bound
drug
antivir
activ
plasma
may
lower
report
vitro
activ
protein
concentr
use
cultur
media
lower
plasma
fifthli
robust
pharmacokinet
data
avail
molecul
subtl
differ
report
pharmacokinet
differ
studi
possibl
analysi
utilis
pharmacokinet
describ
highest
dose
approv
indic
check
ensur
profound
differ
evid
differ
studi
howev
case
higher
dose
andor
frequent
dose
investig
drug
mention
higher
exposur
may
avail
drug
offlabel
dose
sixthli
digitis
pharmacokinet
plot
present
manuscript
repres
mean
median
profil
depend
present
origin
manuscript
mani
drug
present
known
exhibit
high
interindividu
variabl
captur
within
present
analysi
possibl
even
promis
candid
signific
proport
patient
may
subtherapeut
concentr
despit
popul
meanmedian
higher
cmax
advanc
pharmacokinet
model
approach
need
unpick
current
underway
author
seventhli
present
predict
lung
accumul
may
offer
basi
rank
molecul
expect
accumul
organ
ultim
effect
chemoprophylact
approach
like
depend
upon
penetr
critic
matric
upper
airway
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
current
robustli
valid
method
predict
also
gener
accept
method
assess
kpu
employ
predict
support
empir
investig
lung
accumul
final
analysi
assum
drug
need
activ
within
system
compart
order
efficaci
sinc
current
evid
suggest
viru
wide
dissemin
throughout
bodi
logic
assumpt
howev
ultim
efficaci
drug
demonstr
robust
clinic
trial
design
current
analysi
reveal
mani
put
agent
never
like
achiev
target
concentr
necessari
adequ
suppress
normal
dose
condit
critic
candid
medicin
emerg
vitro
antivir
screen
programm
consid
context
expect
exposur
human
possibl
clinic
trial
extrem
time
consum
expens
critic
best
option
progress
robust
analysi
potenti
monoor
combin
therapi
prevent
option
final
would
highli
benefici
activ
data
perform
standardis
protocol
activ
report
valu
better
marker
concentr
requir
suppress
viru
therapeut
relev
level
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
term
cmax
ratio
also
provid
b
amodiaquin
toremifen
estim
exhibit
subtherapeut
pharmacokinet
irrespect
valu
use
similarli
nelfinavir
estim
cmax
valu
higher
irrespect
use
analysi
drug
interpret
highli
depend
upon
report
utilis
underscor
caution
taken
interpret
avail
data
bar
chart
display
cmax
ratio
compound
studi
vitro
antivir
activ
data
avail
recalcul
drug
ratio
deem
provid
plasma
concentr
approv
dose
exert
suffici
system
antivir
activ
drug
ratio
shown
orang
deem
potenti
provid
plasma
concentr
suffici
exert
least
antivir
activ
least
dose
interv
approv
dose
drug
shown
green
predict
exceed
plasma
concentr
twofold
dash
green
line
also
highlight
refer
utilis
data
nitazoxanid
bid
bid
tipranavir
bid
ritonavir
sulfadoxin
pyrimethamin
nelfinavir
bid
indomethacin
tid
atazanavir
qd
ritonavir
hydroxychloroquin
mg
hydroxychloroquin
sulfat
mg
base
administ
day
eltrombobag
singl
dose
lopinavir
mg
mg
ritonavir
chloroquin
administ
day
mefloquin
day
anidulafungin
mg
qd
robust
pharmacokinet
data
unavail
niclosamid
ritonavir
merimepodib
order
conduct
digitis
interrog
molecul
deem
provid
lung
concentr
approv
dose
exert
suffici
pulmonari
antivir
activ
treatment
prevent
strategi
drug
ratio
shown
orang
estim
provid
lung
concentr
suffici
exert
least
antivir
activ
approv
dose
drug
shown
green
predict
exceed
lung
concentr
tenfold
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
